These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 11750353)

  • 1. Cyclosporine dose fractioning might affect renal function in stable heart transplanted patients.
    Baraldo M; Pea F; Poz D; Albanese MC; Livi U; Furlanut M
    Transplant Proc; 2001; 33(7-8):3151-3. PubMed ID: 11750353
    [No Abstract]   [Full Text] [Related]  

  • 2. Follow-up after conversion to Neoral in stable heart transplant recipients.
    Pethig K; Geiger M; Korn A; Grote M; Christians U; Wahlers T
    Transplant Proc; 1996 Aug; 28(4):2282-4. PubMed ID: 8769226
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical impact of Neoral in thoracic organ transplantation.
    Aziz T; el-Gamel A; Keevil B; Krysiak P; Campbell C; Rahman A; Deiraniya A; Yonan N
    Transplant Proc; 1998 Aug; 30(5):1900-3. PubMed ID: 9723326
    [No Abstract]   [Full Text] [Related]  

  • 4. C(2) monitoring of cyclosporine in stable heart transplant patients after two daily and three daily doses.
    Baraldo M; Francesconi A; Barbone F; Tursi V; Livi U; Furlanut M
    Transplant Proc; 2002 Dec; 34(8):3246-8. PubMed ID: 12493435
    [No Abstract]   [Full Text] [Related]  

  • 5. Neoral conversion in stable thoracic transplant patients leads to dose reduction.
    Zaldonis DB; Keenan RJ; Pham SM; Kormos RL; Griffith BP
    Transplant Proc; 1998 Aug; 30(5):1898-9. PubMed ID: 9723325
    [No Abstract]   [Full Text] [Related]  

  • 6. Introduction of mycophenolate mofetil and cyclosporine withdrawal in heart transplant patients with progressive deteriorating renal function.
    Dureau G; Obadia JF; Chuzel M; Boissonnat P
    Transplant Proc; 2000 Mar; 32(2):461-2. PubMed ID: 10715479
    [No Abstract]   [Full Text] [Related]  

  • 7. Neoral conversion study: shift from Sandimmune classic formulation to Neoral in heart and lung transplant patients.
    Svendsen UG; Larsen KR; Allermand H; Thayssen P; Jensen SB; Pettersson G
    Transplant Proc; 1996 Aug; 28(4):2281. PubMed ID: 8769225
    [No Abstract]   [Full Text] [Related]  

  • 8. Effect of prophylactic ganciclovir on renal function and cyclosporine levels after heart transplantation.
    Cantarovich M; Latter D
    Transplant Proc; 1994 Oct; 26(5):2747-8. PubMed ID: 7940863
    [No Abstract]   [Full Text] [Related]  

  • 9. Early renal benefit of rapamycin combined with reduced calcineurin inhibitor dose in pediatric heart transplantation patients.
    Balfour IC; Srun SW; Wood EG; Belsha CW; Marshall DL; Ferdman BR
    J Heart Lung Transplant; 2006 May; 25(5):518-22. PubMed ID: 16678029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of immunosuppression with OKT3 following heart transplantation: kidney function as a criterion for control of protocol duration.
    Rodríguez JA; Crespo-Leiro MG; Paniagua MJ; Muñiz J; Hermida LF; Fojón S; Cuenca JJ; Juffé-Stein A; Castro-Beiras A
    Transplant Proc; 1999 Sep; 31(6):2517-8. PubMed ID: 10500696
    [No Abstract]   [Full Text] [Related]  

  • 11. Long-term impact of discontinued or reduced calcineurin inhibitor in patients with chronic allograft nephropathy.
    Weir MR; Ward MT; Blahut SA; Klassen DK; Cangro CB; Bartlett ST; Fink JC
    Kidney Int; 2001 Apr; 59(4):1567-73. PubMed ID: 11260422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improvement of correlation between oral dose of cyclosporine and cyclosporinemia after substitution of cyclosporine standard presentation by cyclosporine microemulsion one, in 1345 patients with kidney transplantation. Spanish Sandimmune Neoral Conversion Group.
    Gentil Govantes MA; Gómez Ullate P; Errasti P; Fernández Fresnedo G; Capdevila L; Sanz Guajardo A; Cubero JJ
    Transplant Proc; 1998 Aug; 30(5):1658-9. PubMed ID: 9723231
    [No Abstract]   [Full Text] [Related]  

  • 13. Comparative bioavailability of Neoral and Sandimmune in cardiac transplant recipients over 1 year.
    Cooney GF; Jeevanandam V; Choudhury S; Feutren G; Mueller EA; Eisen HJ
    Transplant Proc; 1998 Aug; 30(5):1892-4. PubMed ID: 9723323
    [No Abstract]   [Full Text] [Related]  

  • 14. Long-term safety and efficacy of Neoral in heart transplantation.
    Yonan NA; Aziz T; el-Gamel A; Campbell CS; Rahman AN; Deiraniya AK
    Transplant Proc; 1998 Aug; 30(5):1906-9. PubMed ID: 9723328
    [No Abstract]   [Full Text] [Related]  

  • 15. Conversion from regular cyclosporine to microemulsion cyclosporine following heart transplantation.
    Heroux AL; LeBlanc MH; Beaudoin D; Simard S; Coulombe DA; Gleeton O; Lemieux MD; Doyle DP
    Transplant Proc; 1996 Dec; 28(6):3145-8. PubMed ID: 8962219
    [No Abstract]   [Full Text] [Related]  

  • 16. Conversion from once-daily Sandimmune cyclosporine to once-daily Neoral in renal transplant patients.
    Arvind C; Vathsala A; Woo KT
    Transplant Proc; 2000 Nov; 32(7):1681-2. PubMed ID: 11119890
    [No Abstract]   [Full Text] [Related]  

  • 17. Induction therapy with cyclosporine and without cytolytic agents results in a low incidence of acute rejection without significant renal impairment in heart transplant patients.
    Jazzar A; Fagiuoli S; Sisson S; Zuhdi N; Cooper DK
    Transplant Proc; 1994 Oct; 26(5):2749. PubMed ID: 7940864
    [No Abstract]   [Full Text] [Related]  

  • 18. Estimated area-under-the-curve monitoring of Neoral in a stable pediatric renal transplant population: one-year experience.
    Lemire J; Capparelli EV; MacDonald D; Benador N; Reznik VM; Mendoza SA; Griswold WR
    Transplant Proc; 1998 Aug; 30(5):1983-4. PubMed ID: 9723361
    [No Abstract]   [Full Text] [Related]  

  • 19. Effect of Sandimmune cyclosporine on renal blood flow and function in heart transplant recipients.
    Chung G; Walker S; Vadher B; Murphy F; Leaver N; Banner N
    Transplant Proc; 1998 Jun; 30(4):1147-8. PubMed ID: 9636464
    [No Abstract]   [Full Text] [Related]  

  • 20. Cyclosporine lowering with everolimus or mycophenolate to preserve renal function in heart recipients: a randomized study.
    Potena L; Bianchi IG; Magnani G; Masetti M; Coccolo F; Fallani F; Russo A; Grigioni F; Branzi A; Ponticelli C
    Transplantation; 2010 Jan; 89(2):263-5. PubMed ID: 20098293
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.